MTOR and hyperlipidemia: Hyperlipidemia is frequently observed in patients treated with VEGFR (vascular endothelial growth factor receptor)–TKIs [13], as well as mTOR inhibitors (such as rapamycin, temsirolimus and everolimus) [12].